Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Open Access
- 25 February 2013
- journal article
- a continuing-medical-education-series
- Published by Wiley in American Journal of Hematology
- Vol. 88 (3) , 225-235
Abstract
Disease overview: Multiple myeloma accounts for approximately 10% of hematologic malignancies.Diagnosis: The diagnosis requires 10% or more clonal plasma cells on bone marrow examination or a biopsy proven plasmacytoma plus evidence of associated end‐organ damage. In addition, the presence of 60% or more clonal plasma cells in the marrow is also considered as myeloma regardless of the presence or absence of end‐organ damage.Risk stratification: In the absence of concurrent trisomies, patients with 17p deletion, t(14;16), and t(14;20) are considered to have high‐risk myeloma. Patients with t(4;14) translocation are considered intermediate‐risk. All others are considered as standard‐risk.Risk‐adapted initial therapy: Standard‐risk patients can be treated with lenalidomide plus low‐dose dexamethasone (Rd), or a bortezomib‐containing triplet such as bortezomib, cyclophosphamide, dexamethasone (VCD). Intermediate‐risk and high‐risk patients require a bortezomib‐based triplet regimen. In eligible patients, initial therapy is given for approximately 4 months followed by autologous stem cell transplantation (ASCT). Standard‐risk patients can opt for delayed ASCT if stem cells can be cryopreserved. In patients are not candidates for transplant, initial therapy is given for approximately 12–18 months.Maintenance therapy: After initial therapy, lenalidomide maintenance is considered for standard‐risk patients who are not in very good partial response or better, while maintenance with a bortezomib‐based regimen should be considered in pateints with intermediate or high‐risk myeloma.Management of refractory disease: Patients with indolent relapse can be treated first with two‐drug or three‐drug combinations. Patients with more aggressive relapse often require therapy with a combination of multiple active agents. Am. J. Hematol. 88:225–235, 2013.Keywords
This publication has 122 references indexed in Scilit:
- Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical RecognitionMayo Clinic Proceedings, 2012
- Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyThe Lancet, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- The molecular characterization and clinical management of multiple myeloma in the post-genome eraLeukemia, 2009
- Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myelomaLeukemia, 2009
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialLeukemia, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myelomaLeukemia, 2008
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006